Vanguard Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$423K Hold
36,195
– – ﹤0.01% 2240
2026
Q2
$705K Buy
36,195
+12,367
+52% +$224K ﹤0.01% 2048
2026
Q1
$444K Buy
+23,828
New +$395K ﹤0.01% 2150

Other funds holding MLTX

Vanguard Asset Management's MLTX Position: Q3 2026 in Review

Vanguard Asset Management held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2026 at 36,195 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

Vanguard Asset Management first reported a position in MLTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $705K in Q2 2026. 168 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Vanguard Asset Management held 36,195 shares of MoonLake Immunotherapeutics worth $423K as of Q3 2026.
  • Vanguard Asset Management left its MoonLake Immunotherapeutics share count unchanged in Q3 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2240 holding.
  • Vanguard Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's MoonLake Immunotherapeutics position peaked at $705K in Q2 2026.
  • 168 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.